^
Association details:
| Biomarker: | GUCY2C expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | IM96 CAR-T cells (GUCY2C-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1018O - Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer
Published date:
10/16/2023
Excerpt:
The response in pts with moderate-to-strong GCC expression in ≥30% of tumor cells was 100% DCR, and with this prerequisite, tumor reduction was observed in 100% pts when the IM96 dose was ≥6×108...IM96 was well tolerated and showed encouraging efficacy. The clinical response is correlated with tumor GCC expression, infusion dose, and CAR-T expansion level.
Trial ID:
